NAV

Mycobacterium w. Vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mycobacterium w. Vaccine
DrugBank Accession Number
DB15798
Background

The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis. Its use has shown clinical improvement, rapid bacterial clearance, and enhanced immune responses to Mycobacterium leprae antigens.

M.w immunization activates macrophages and lymphocytes upon administration. It has protective efficacy against M. tuberculosis and M. leprae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Heat Killed Mycobacterium W Immunomodulator
  • M.w
  • Mycobacterium W Vaccine
  • Mycobacterium w. Vaccine
  • Suspension of heat killed (autoclaved) Mycobacterium w
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Immuvac (Cadila Pharmaceuticals Ltd.) / Sepsivac (Cadila Pharmaceuticals Ltd.)

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Gupta A, Geetha N, Mani J, Upadhyay P, Katoch VM, Natrajan M, Gupta UD, Bhaskar S: Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immun. 2009 Jan;77(1):223-31. doi: 10.1128/IAI.00526-08. Epub 2008 Nov 3. [Article]
  2. Khullar G, Narang T, Nahar Saikia U, Dogra S: Generalized granulomatous dermatitis following Mycobacterium w (Mw) immunotherapy in lepromatous leprosy. Dermatol Ther. 2017 Mar;30(2). doi: 10.1111/dth.12441. Epub 2016 Nov 28. [Article]
  3. Katoch K, Singh P, Adhikari T, Benara SK, Singh HB, Chauhan DS, Sharma VD, Lavania M, Sachan AS, Katoch VM: Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine. 2008 Feb 26;26(9):1228-34. doi: 10.1016/j.vaccine.2007.12.025. Epub 2008 Jan 10. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentTuberculosis (TB)2
3CompletedTreatmentTuberculous Pericarditis1
3Unknown StatusPreventionCoronavirus Disease 2019 (COVID‑19)1
3Unknown StatusTreatmentCoronavirus Disease 2019 (COVID‑19)1
Not AvailableCompletedTreatmentCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 05, 2020 16:05 / Updated at July 18, 2023 22:58